RxDoctor Payments Data

Bryan Young, MD

Internal Medicine · Reno, NVNPI 1851452452

Payments from drug & device makers

$1,598in general payments, 2019–2025

Across 32 payments — averaging $49.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$225
  • Bayer$207
  • Amarin Pharma, Inc.$129
  • Lilly USA, LLC$128
  • Amgen$126
  • Boehringer Ingelheim$124
  • plus $658 from 11 others

What the payments were for

  • Food & beverage$1,54196%
  • Education$574%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,598 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$142,937
Medicare patients
297
Services billed
12,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis13$337,193
EliquisApixaban66$87,622
JardianceEmpagliflozin26$43,050
RexultiBrexpiprazole27$41,896
OzempicSemaglutide22$38,475
XareltoRivaroxaban18$30,057
Praluent PenAlirocumab26$22,967
Repatha SureclickEvolocumab18$19,862
MyrbetriqMirabegron21$18,538
Breo ElliptaFluticasone/Vilanterol21$14,357
MounjaroTirzepatide11$11,553
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,047
SynthroidLevothyroxine Sodium94$10,534
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$10,200
TrintellixVortioxetine Hydrobromide16$7,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis, Paxlovid$122$426,244105 claims
Boehringer IngelheimJardiance$124$43,05026 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$15$29,40952 claims
Lilly USA, LLCMounjaro$128$11,55311 claims
AbbVieSynthroid$225$10,53494 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →